Cefadroxil
| Evidensnivå: L5 | Förutsagda indikationer: 0 st |
Innehållsförteckning
CEFADROXIL: Drug Repurposing Evaluation Report
One-Sentence Summary
Cefadroxil is a first-generation cephalosporin antibiotic commonly used for bacterial infections of the skin, urinary tract, and upper respiratory tract. The TxGNN model has not generated any predicted new indications for this drug, and the evidence pack contains significant data gaps including mechanism of action and regulatory safety information.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (known: bacterial infections including UTI, pharyngitis, skin infections) |
| Predicted New Indication | None — no TxGNN predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (No predictions or supporting studies) |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, no TxGNN prediction has been generated for cefadroxil, so there is no new indication to evaluate for mechanistic plausibility.
Cefadroxil (DrugBank ID: DB01140) is a first-generation cephalosporin, a class of β-lactam antibiotics that work by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). Detailed mechanism of action data was not available in the evidence pack (flagged as Data Gap DG002), though the drug's pharmacology is well-characterized in the literature.
Without a predicted indication from the TxGNN model, no mechanism-to-disease bridging analysis can be performed at this time. This candidate should be revisited once the prediction pipeline has been run and validated predictions are available.
Clinical Trial Evidence
Currently no predicted indication available — clinical trial search not applicable.
Literature Evidence
Currently no predicted indication available — literature search not applicable.
Taiwan Market Information
Cefadroxil has no active marketing authorizations in Taiwan (TFDA). No licenses were found in the regulatory query conducted on 2026-03-29.
Safety Considerations
Please refer to the package insert for safety information.
Note: Key warnings, contraindications, and drug interaction data were all unavailable in this evidence pack (Data Gaps DG001). The TFDA package insert query returned 1 result but parsed safety fields remain empty. It is recommended to retrieve and parse the full package insert PDF from the TFDA website to complete the safety profile.
Conclusion and Next Steps
Decision: Hold
Rationale: No TxGNN-predicted indications exist for cefadroxil at this time, and the drug is not currently marketed in Taiwan. Without a target indication, there is no actionable repurposing hypothesis to evaluate.
To proceed, the following is needed:
- Run the TxGNN prediction pipeline for cefadroxil (DB01140) and generate candidate indications
- Fill Data Gap DG002: Retrieve detailed mechanism of action from DrugBank API
- Fill Data Gap DG001 (Blocking): Download and parse the TFDA package insert PDF for safety warnings and contraindications
- Reassess market access feasibility given the drug's current unlicensed status in Taiwan
- Once predictions are available, collect clinical trial and literature evidence for the top-ranked indication(s)
Ansvarsfriskrivning
Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.